6698-57-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
6-chloro[1,2,4]triazolo[4,3-b]pyridazin-8-amine is utilized as a key intermediate in the synthesis of new compounds with potential therapeutic applications. Its unique molecular structure allows for the creation of drugs that can target specific biological pathways or receptors, contributing to the development of innovative treatments for various diseases and conditions.
Used in Materials Science and Nanotechnology:
Due to its distinct chemical properties, 6-chloro[1,2,4]triazolo[4,3-b]pyridazin-8-amine may also have potential applications in materials science and nanotechnology. It could be employed in the design and synthesis of advanced materials with specific properties, such as improved stability, reactivity, or selectivity, which can be beneficial in various industrial and technological applications.

Upstream product

• 64-18-6 formic acid 
• 934-26-9 4-amino-6-chloro-3-hydrazinopyridazine 

Downstream Products

• 6583-39-7 [1,2,4]triazolo[4,3-b]pyridazin-8-ylamine 
• 1569870-23-0 [2-(4-methoxy-phenyl)-ethyl]-[1,2,4]triazolo[4,3-b]pyridazin-8-yl-amine 
• 1569870-27-4 4-[2-([1,2,4]triazolo[4,3-b]pyridazin-8-ylamino)-ethyl]-phenol 
• 81450-45-5 l-N-(1-phenyl-1-ethyl)pyrazino<2,3-d>-1,2,4-triazolo<4,3-b>pyridazin-6-amine 
• 81450-45-5 d-N-(1-phenyl-1-ethyl)pyrazino<2,3-d>-1,2,4-triazolo<4,3-b>pyridazin-6-amine 
• 81450-44-4 N-benzylpyrazino<2,3-d>-1,2,4-triazolo<4,3-b>pyridazin-6-amine 
• 81450-33-1 6-chloropyrazino<2,3-d>-1,2,4-triazolo<4,3-b>pyridazine 

Relevant academic research and scientific papers

GPR139 RECEPTOR MODULATORS

Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Searching for selective tankyrases (TNKSs) inhibitors, a new small series of 6,8-disubstituted triazolo[4,3-b]piridazines has been synthesized and characterized biologically. Structure-based optimization of the starting hit compound NNL (3) prompted us to the discovery of 4-(2-(6-methyl-[1,2,4] triazolo[4,3-b]pyridazin-8-ylamino)ethyl)phenol (12), a low nanomolar selective TNKSs inhibitor working as NAD isostere as ascertained by crystallographic analysis. Preliminary biological data candidate this new class of derivatives as a powerful pharmacological tools in the unraveling of TNKS implications in physiopathological conditions.